Suggested remit - To appraise the clinical and cost effectiveness of entrectinib within its proposed marketing authorisation for treating NTRK fusion-positive advanced solid tumours
 
Status In progress
Process STA 2018
ID number 1512

Provisional Schedule

Expected publication 12 February 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Roche (entrectinib)
  Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups GIST UK
  Roy Castle Lung Cancer Foundation
  Sarcoma UK

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Bayer
  Janssen-Cilag Ltd
  Pfizer
  Servier Laboratories Ltd
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
20 November 2019 Committee meeting
08 March 2019 Invitation to participate
14 November 2018 - 12 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance